Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-23

Clinical Trial Update: Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of Mongersen (GED-0301) for active Crohn's disease was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Mongersen (GED-0301)

Snippet

Sponsor: Celgene | Conditions: Crohn Disease | Phase 3 | Status: TERMINATED | Results posted: 2019-01-23